Form 4: Solid Biosciences CTO Sells Shares for Tax Purposes

Solid Biosciences' Chief Technology Officer, Paul Herzich, sold 2,701 shares of common stock at $5.11 per share to cover tax obligations following the vesting of restricted stock units.

Summary

• Paul Herzich, Chief Technology Officer of Solid Biosciences Inc., acquired 7,239 shares of common stock on December 2, 2025, through the vesting of Restricted Stock Units (RSUs).
• The RSUs were granted on December 2, 2022, and vest over four years, with 25% vesting on each anniversary of the grant date.
• On December 3, 2025, Mr. Herzich disposed of 2,701 shares of common stock at a price of $5.11 per share.
• This sale was a "sell-to-cover" transaction, executed to satisfy withholding taxes related to the RSU vesting, and was not a discretionary trade.
• The transaction was made pursuant to a Rule 10b5-1(c) plan adopted on August 16, 2024.
• Following these transactions, Mr. Herzich beneficially owns 26,622 shares of Solid Biosciences common stock.
• His beneficial ownership prior to the disposition included 1,835 and 1,861 shares acquired under the Employee Stock Purchase Plan on May 30, 2025, and November 28, 2025, respectively.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary 'sell-to-cover' transaction by a key executive following RSU vesting. This is a neutral event, neither significantly positive nor negative for the company's outlook.

Positives

• The vesting of 7,239 Restricted Stock Units indicates continued compensation and retention of a key executive.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating pre-planned, non-discretionary sales.

Negatives

• A disposition of shares by an insider, even for tax purposes, reduces their direct equity stake in the company.

Future Outlook

No specific future outlook or guidance is provided in this Form 4.

Management Comments

• This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich.

Industry Context

This Form 4 details a routine insider transaction related to equity compensation. It does not provide information to analyze broader industry trends or competitors.

Related Party Transactions

• The transactions involve an executive's equity compensation (RSU vesting and subsequent sell-to-cover) and participation in the company's Employee Stock Purchase Plan (ESPP), which are standard related party dealings in the context of executive compensation.

Stakeholder Impact

• Shareholders: The slight reduction in the CTO's direct ownership is minimal and offset by the non-discretionary nature of the sale. The vesting itself indicates continued executive alignment through equity.
• Employees: The mention of the Employee Stock Purchase Plan (ESPP) indicates ongoing employee equity participation programs.

Key Dates

Recommendation

This Form 4 details a routine, non-discretionary "sell-to-cover" transaction by a Chief Technology Officer to cover tax obligations arising from RSU vesting. Such transactions are common and pre-planned under Rule 10b5-1, and therefore do not typically signal a change in management's confidence or the company's fundamentals. The filing provides no new information that would warrant a change in investment thesis, thus a 'hold' recommendation is appropriate as it maintains the current stance without suggesting buying or selling based solely on this administrative filing.

Keywords

Solid Biosciences, SLDB, Paul Herzich, Chief Technology Officer, CTO, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Vesting, Sell-to-Cover, Equity Compensation, Rule 10b5-1